Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9JK1

Crystal structure of CDK12/Cyclin K in complex with covalent inhibitor YJZ5118

これはPDB形式変換不可エントリーです。
9JK1 の概要
エントリーDOI10.2210/pdb9jk1/pdb
分子名称Cyclin-dependent kinase 12, Cyclin-K, 1,2-ETHANEDIOL, ... (7 entities in total)
機能のキーワードkinase, covalent inhibitor, selective, transferase
由来する生物種Homo sapiens (human)
詳細
タンパク質・核酸の鎖数4
化学式量合計143760.22
構造登録者
Huang, W.X.,Zhang, P.J.,Yang, J.Z.,Ding, K. (登録日: 2024-09-14, 公開日: 2025-05-07)
主引用文献Yang, J.,Chang, Y.,Zhou, K.,Huang, W.,Tien, J.C.,Zhang, P.,Liu, W.,Zhou, L.,Zhou, Y.,Ren, X.,Mannan, R.,Mahapatra, S.,Zhang, Y.,Hamadeh, R.,Ervine, G.,Wang, Z.,Wang, G.X.,Chinnaiyan, A.M.,Ding, K.
Discovery of YJZ5118 : A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition.
J.Med.Chem., 68:6718-6734, 2025
Cited by
PubMed Abstract: Cyclin-dependent kinases 12 and 13 (CDK12/13) have emerged as promising therapeutic targets for castration-resistant prostate cancer (CRPC) and other human cancers. Despite the development of several CDK12/13 inhibitors, challenges remain in achieving an optimal balance of potency, selectivity and pharmacokinetic properties. Here, we report the discovery of , a novel, potent and highly selective covalent inhibitor of CDK12/13 with reasonable pharmacokinetic profiles. effectively inhibited CDK12 and CDK13 with IC values of 39.5 and 26.4 nM, respectively, while demonstrating high selectivity over other CDKs. Mass spectrometry analysis, cocrystal structure determination, and pulldown-proteomic experiments confirmed the compound's covalent binding mode with CDK12/13. Functionally, efficiently suppressed the transcription of DNA damage response genes, induced DNA damage, and triggered apoptosis. Moreover, the compound significantly inhibited the proliferation of multiple tumor cell lines, particularly prostate cancer cells. Notably, exhibited synergistic effects with Akt inhibitors both in vitro and in vivo.
PubMed: 40080446
DOI: 10.1021/acs.jmedchem.5c00127
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.72 Å)
構造検証レポート
Validation report summary of 9jk1
検証レポート(詳細版)ダウンロードをダウンロード

236620

件を2025-05-28に公開中

PDB statisticsPDBj update infoContact PDBjnumon